Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of oral CEP-701 in previously treated patients with hematologic or non-hematologic malignancies
2005-005542-39Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lestaurtinib in hematopoietic malignancies and Nonhematologic neoplasms, sponsored by Cephalon, Inc. Primary endpoint: Safety and tolerability. Started Feb 2006; status: completed.
02
Drugs
lestaurtinib
03
Conditions
hematopoietic malignanciesNonhematologic neoplasms
Beyond the preview
Go deeper on 2005-005542-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005542-39.